Results 231 to 240 of about 52,371 (280)

DOT1L shapes ncPRC1 target gene repression to maintain germinal center B-cell identity in diffuse large B-cell lymphoma.

Blood
Göbel C, Niccolai R, Gregoricchio S, de Groot MHP, Kneefel S, Kreft M, Kuiken HJ, Lieftink C, Eickhoff N, Hoekman L, Bleijerveld O, Zwart W, Beijersbergen RL, van Leeuwen F, Jacobs H.   +14 more
europepmc   +1 more source

Estimating the Proportion of Transplant-Eligible Patients in Diffuse Large B-Cell Lymphoma: Insights from German Hospital Billing Data.

Oncol Res Treat
Froitzheim AC, Kurte MS, Poos T, Holtick U, Kron F.   +4 more
europepmc   +1 more source

The Immunology of DLBCL

Cancers, 2023
Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy and is the most common type of malignant lymphoid neoplasm. While some DLBCLs exhibit strong cell-autonomous survival and proliferation activity, others depend on interactions with non-malignant cells for their survival and proliferation.
Taishi Takahara, Toyonori Tsuzuki, Akira Satou   +2 more
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Integration of PET in DLBCL

Seminars in Hematology, 2023
F-fluorodeoxyglucose positron emission tomography-computerized tomography (18FDG-PET/CT) is the gold-standard imaging modality for staging and response assessment for most lymphomas. This review focuses on the utility of 18FDG-PET/CT, and its role in staging, prognostication and response assessment in diffuse large B-cell lymphoma (DLBCL), including ...
Katharine L Lewis, Judith Trotman
openaire   +2 more sources

DLBCL

Onkologische Welt, 2023
Bei Patienten mit diffus großzelligem B-Zell-Lymphom (DLBCL) besitzt zirkulierende Tumor-DNA (ctDNA) im Rahmen einer Liquid Biopsy einen präzisen prognostischen Aussagewert. Prof. Sirpa Leppä, Helsinki (Finnland), erläuterte zahlreiche Vorteile und Anwendungsmöglichkeiten. Mit Bestimmung der ctDNA kann vor Therapiebeginn ein Risiko-Staging durchgeführt
openaire   +1 more source

Disparity Analysis of Clinicopathologic Hallmarks between Transformed DLBCL and Primary DLBCL

Clinical Laboratory, 2022
A variety of indolent lymphomas, particularly marginal zone lymphoma (MZL) and follicular lymphoma (FL) can be histologically transformed to diffuse large B-cell lymphoma (DLBCL). Little is known about the disparity of clinicopathologic characteristics between transformed DLBCL (tDLBCL) and primary DLBCL (pDLBCL).This retrospective study analyzed the ...
Cai, Sun, Ziyuan, Shen, Zhenzhen, Bian, Yuanyuan, Ma, Jiaqin, Li, Yuhan, Ma, Xuguang, Song, Dongmei, Yan, Hui, Liu, Zhenyu, Li, Wei, Sang, Kailin, Xu   +11 more
openaire   +2 more sources

Sequencing therapy in relapsed DLBCL

Hematology, 2022
Abstract Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy worldwide, comprising approximately 30% of all lymphomas. Currently, 50% to 60% of patients diagnosed with DLBCL are alive at 5 years and cured with modern therapy, but about 10% to 15% of patients are refractory to first-line therapy, and an additional
Christopher R, Flowers, Oreofe O, Odejide   +1 more
openaire   +2 more sources

Refractory DLBCL: Challenges and Treatment

Clinical Lymphoma Myeloma and Leukemia, 2022
Despite a greater understanding of pathologic factors that increase the chance for treatment failure, initial therapy of diffuse large B cell lymphoma (DLBCL) has not evolved from R/CHOP. Although it was anticipated that the genetic underpinnings of the cell or origin would dramatically change treatment, thus far, this has not been realized. Similarly,
Mendel Goldfinger, Dennis L. Cooper
openaire   +2 more sources